Robert Korcal, DO
Family Medicine · Las Vegas, NVNPI 1558329839
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 24.8% of the total. Reporting peaked in 2021 at $2,323 and has fallen 66.9% since, to $769 in 2025. Among family medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $57.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$990
- Novo Nordisk$911
- Pfizer$807
- AstraZeneca$771
- Boehringer Ingelheim$613
- plus $3K from 18 others
What the payments were for
- Food & beverage$9,463100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $2,345 |
| Amgen | 11 | $990 |
| Novo Nordisk | 14 | $911 |
| Pfizer | 36 | $807 |
| AstraZeneca | 10 | $771 |
| Boehringer Ingelheim | 22 | $613 |
| Abbott | 4 | $467 |
| Johnson & Johnson | 5 | $281 |
| OPKO Pharmaceuticals, LLC | 2 | $280 |
| Esperion Therapeutics, Inc. | 3 | $263 |
| Biohaven Pharmaceuticals, Inc. | 3 | $262 |
| Astellas Pharma US Inc | 2 | $247 |
| Nevro Corp. | 1 | $189 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $186 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $167 |
| Merck | 8 | $131 |
| Phathom Pharmaceuticals, Inc. | 1 | $128 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $102 |
| Novartis | 1 | $101 |
| Lilly USA, LLC | 4 | $54 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Intuitive Surgical | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,463 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 98 | $112,669 |
| EliquisApixaban | 90 | $91,174 |
| OzempicSemaglutide | 53 | $71,111 |
| TrulicityDulaglutide | 39 | $56,305 |
| JanuviaSitagliptin Phosphate | 26 | $36,938 |
| FarxigaDapagliflozin Propanediol | 18 | $27,598 |
| EntrestoSacubitril/Valsartan | 12 | $24,868 |
| XareltoRivaroxaban | 15 | $21,363 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $12,960 |
| Rosuvastatin Calcium | 548 | $7,723 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 141 | $6,217 |
| Omeprazole | 260 | $5,711 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,386 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,292 |
| Atorvastatin Calcium | 512 | $4,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $613 | $112,66998 claims |
| PfizerEliquis | $807 | $91,17490 claims |
| Novo NordiskOzempic | $911 | $71,11153 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30, Humulin N | $54 | $62,11163 claims |
| MerckJanuvia | $131 | $36,93826 claims |
| AstraZenecaFarxiga, Symbicort | $771 | $32,98539 claims |
| NovartisEntresto | $101 | $24,86812 claims |
| Johnson & JohnsonXarelto | $281 | $21,36315 claims |
| AbbVieSynthroid | $2,345 | $1,81815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Warren MagnusLas Vegas$70K
- Kimberly AdamsLas Vegas$51K
- Mandeep GillLas Vegas$24K
- Francis JimenezLas Vegas$20K
- Ryan HuangLas Vegas$18K
- Ma Francesca ChamianLas Vegas$17K
- Leo CapobiancoLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.